TSLP and asthma: Tezepelumab, a human monoclonal antibody that specifically targets thymic stromal lymphopoietin (TSLP), an epithelial cytokine that is implicated in the initiation and persistence of asthma airway inflammation, is a relatively newly approved biologic addition in the field of severe asthma management and is used in conjunction with other maintenance treatment of severe asthma.